Serper Marina, Wolf Michael S, Parikh Nikhil A, Tillman Holly, Lee William M, Ganger Daniel R
*Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA †Health Literacy and Learning Program, Division of General Internal Medicine #Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine §Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago ‡Department of Learning Sciences, School of Education and Social Policy, Northwestern University, Evanston, IL ∥Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC ¶Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX.
J Clin Gastroenterol. 2016 Jan;50(1):85-91. doi: 10.1097/MCG.0000000000000378.
Acetaminophen (APAP) is the most common cause of acute liver failure (ALF) in the west. It is unknown if APAP overdose in combination with diphenhydramine or opioids confers a different clinical presentation or prognosis. Study objectives were to compare (1) baseline patient characteristics; (2) initial clinical presentation; and (3) clinical outcomes among patients with ALF due to APAP alone or in combination with diphenhydramine or opioids.
We analyzed 666 cases of APAP-related liver failure using the Acute Liver Failure Study Group database from 1998 to 2012. The database contains detailed demographic, laboratory, and clinical outcome data, including hemodialysis, transplantation, and death and in-hospital complications such as arrhythmia and infection.
The final sample included 666 patients with APAP liver injury. A total 30.3% of patients were overdosed with APAP alone, 14.1% with APAP/diphenhydramine, and 56.6% with APAP/opioids. Patients taking APAP with opioids were older, had more comorbidities, and were more likely to have unintentional overdose (all P<0.0001). On presentation, 58% in the APAP/opioid group had advanced encephalopathy as compared with 43% with APAP alone (P=0.001) The APAP/diphenhydramine group presented with the highest serum aminotransferase levels, no differences in laboratory values were noted at 3 days postenrollment. No significant differences were observed in clinical outcomes among the groups.
Most patients with APAP-induced ALF were taking APAP combination products. There were significant differences in patient characteristics and clinical presentation based on the type of product ingested, however, there were no differences noted in delayed hepatotoxicity or clinical outcomes.
对乙酰氨基酚(APAP)是西方急性肝衰竭(ALF)最常见的病因。目前尚不清楚APAP过量联合苯海拉明或阿片类药物是否会导致不同的临床表现或预后。本研究的目的是比较(1)患者基线特征;(2)初始临床表现;以及(3)单独使用APAP或联合苯海拉明或阿片类药物导致ALF的患者的临床结局。
我们使用急性肝衰竭研究组1998年至2012年的数据库分析了666例与APAP相关的肝衰竭病例。该数据库包含详细的人口统计学、实验室检查和临床结局数据,包括血液透析、移植、死亡以及心律失常和感染等住院并发症。
最终样本包括666例APAP肝损伤患者。其中,30.3%的患者单独过量服用APAP,14.1%的患者过量服用APAP/苯海拉明,56.6%的患者过量服用APAP/阿片类药物。服用APAP与阿片类药物的患者年龄更大,合并症更多,且更有可能发生意外过量服药(所有P<0.0001)。就诊时,APAP/阿片类药物组58%的患者出现晚期肝性脑病,而单独使用APAP的患者为43%(P=0.001)。APAP/苯海拉明组血清转氨酶水平最高,入院3天时实验室检查值无差异。各组临床结局无显著差异。
大多数APAP所致ALF患者服用的是APAP复方制剂。根据摄入产品类型的不同,患者特征和临床表现存在显著差异,然而,在迟发性肝毒性或临床结局方面未观察到差异。